These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 30584073)
1. Direct Targeting of Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073 [TBL] [Abstract][Full Text] [Related]
2. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma. Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807 [TBL] [Abstract][Full Text] [Related]
3. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295 [TBL] [Abstract][Full Text] [Related]
4. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN. Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116 [TBL] [Abstract][Full Text] [Related]
5. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma. Hallett RM; Seong AB; Kaplan DR; Irwin MS Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification. Xu Y; Chen X; Lin L; Chen H; Yu S; Li D Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710 [TBL] [Abstract][Full Text] [Related]
7. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377 [TBL] [Abstract][Full Text] [Related]
8. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines. Aygun N; Altungoz O Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774 [TBL] [Abstract][Full Text] [Related]
14. Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity. Alptekin A; Ye B; Yu Y; Poole CJ; van Riggelen J; Zha Y; Ding HF Oncogene; 2019 Dec; 38(50):7504-7520. PubMed ID: 31444411 [TBL] [Abstract][Full Text] [Related]
15. Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression. Gao J; Jung M; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ Cancer Res; 2020 Sep; 80(17):3706-3718. PubMed ID: 32651259 [TBL] [Abstract][Full Text] [Related]
16. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519 [TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. Marrano P; Irwin MS; Thorner PS Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma. Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634 [TBL] [Abstract][Full Text] [Related]
19. Activation of Aryl Hydrocarbon Receptor by Kynurenine Impairs Progression and Metastasis of Neuroblastoma. Wu PY; Yu IS; Lin YC; Chang YT; Chen CC; Lin KH; Tseng TH; Kargren M; Tai YL; Shen TL; Liu YL; Wang BJ; Chang CH; Chen WM; Juan HF; Huang SF; Chan YY; Liao YF; Hsu WM; Lee H Cancer Res; 2019 Nov; 79(21):5550-5562. PubMed ID: 31431462 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma. Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]